

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

UCSD-AML1

RRID:CVCL_1853

Type: Cell Line

Proper Citation

RRID:CVCL_1853

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1853

Proper Citation: RRID:CVCL_1853

Description: Cell line UCSD-AML1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Acute myeloid leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2) GATA2, MECOM

Defining Citation: [PMID:1698479](#), [PMID:9195772](#), [PMID:15229617](#)

Comments: Characteristics: CSF1 or CSF2 or IL6 dependent.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: UCSD-AML1

Synonyms: UCSD/AML1, UCSD/AML-1, UCSD/AML 1

Cross References: BioSample:SAMN03473441, Cosmic:787484, Cosmic:975308, Cosmic:1281358, Cosmic:2306242, Cosmic:2378089, Cosmic:2733529, DSMZ:ACC-691, DSMZCellDive:ACC-691, Wikidata:Q54989712

ID: CVCL_1853

Record Creation Time: 20220427T221646+0000

Record Last Update: 20260905T182630+0000

Ratings and Alerts

No rating or validation information has been found for UCSD-AML1.

No alerts have been found for UCSD-AML1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Fiskus W, et al. (2026) Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. HemaSphere, 10(1), e70289.

Birdwell CE, et al. (2025) BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia.

Birdwell CE, et al. (2024) Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia, 38(3), 545.

Riedel SS, et al. (2021) Intrinsically disordered Meningioma-1 stabilizes the BAF complex to cause AML. Molecular cell, 81(11), 2332.